"Because the pharma companies with approved GLP-1s do not pursue addiction treatment, a large scale trial and FDA indication will not happen on its own. Without a strategic public effort along these lines, we may be waiting 10-15 years before a GLP-1 indication becomes available.

If we are successful in launching large-scale studies, this will be an unprecedented non-profit scientific endeavor, filling the gap between public research agencies and pharma, and collaborating with both along the way. We’re excited."